Gsk3368715 closed clinical trial
WebMay 18, 2024 · Since the dysregulation of protein arginine methylation is closely associated with cancer development, protein arginine methyltransferases (PRMTs) have garnered significant interest as novel... WebApr 11, 2024 · This study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), food effect and preliminary clinical activity of GSK33368715 in participants with …
Gsk3368715 closed clinical trial
Did you know?
WebA Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid … WebDec 24, 2024 · GSK3368715 is a potent reversible inhibitor of all five type I PRMTs. Profiling with this compound across a panel of 249 cancer cell lines, representing 12 tumor types demonstrated cytotoxicity...
WebSo far, three PRMT inhibitors have entered clinical trials, including PRMT5 inhibitor GSK3326595 and JNJ-64619178 as well as PRMT1 inhibitor GSK3368715. PRMT inhibitors with novel mechanism of action and good drug-like properties may shed new light on drug research and development progress. WebSep 10, 2024 · First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) GlaxoSmithKline 20 May 2024 First Received: September 10, 2024 Last Updated: May 20, 2024 Phase: Phase 1 Start Date: October 22, 2024 Overall Status: Terminated Estimated Enrollment: 31 Overview
WebGSK3368715 is a potent, reversible, SAM uncompetitive inhibitor of type I PRMTs that produces a shift in arginine methylation states on hundreds of substrates from ADMA to … WebClinical Trials Detail Study #2024-0666 A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of …
WebApr 8, 2024 · The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was recently implicated as a synthetic lethal target in cancers with deletion of the methylthioadenosine phosphorylase (MTAP) gene, wh... Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP …
WebDec 17, 2024 · GSK3368715 is a small molecule inhibitor of type I PRMTs currently in clinical development. Here, we evaluate the effect of type I PRMT inhibition on arginine methylation in normal human peripheral blood mononuclear cells and utilize a broad proteomic approach to identify type I PRMT substrates. pop art factory clermont ferrandWebMay 23, 2011 · GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers … sharepoint csom tls 1.2WebJul 29, 2024 · GSK3368715 induces time- and dose-dependent accumulation of DLBCL cells in sub-G 1. In contrast, the cytostatic OCI-Ly1 line accumulation of sub-G 1 only detects at the highest concentration of GSK3368715. In vivo, GSK3368715 can completely inhibit tumor growth or cause regressions of tumor models. sharepoint csom sdkWebGsk3368715 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating gsk3368715, 1 is phase 1 (0 open). Diffuse large B-cell … sharepoint csom .net standardWebMar 10, 2024 · Notably, the type I PRMT inhibitor GSK3368715 is in phase I clinical trials for the treatment of diffuse large B-cell lymphoma and solid tumors (clinicaltrials.gov identifier number: NCT03666988). Additionally, PRMT5 inhibitors JNJ-64619178 and GSK3326595 are currently in phase I clinical trials (ClinicalTrials.gov identifier numbers ... pop art factory clermontWebAbout Cancer Cancer Types Research Grants & Training News & Events About NCI Home About Cancer Cancer Treatment Clinical Trials Information Find NCI-Supported … sharepoint csom update list itemWebJun 16, 2024 · Shares closed Tuesday at $12.84 apiece. ... shouldering all of the clinical trial expenses for the pol theta program. If GSK is able to commercialize a pol theta drug, Ideaya stands to earn ... sharepoint csom upload file to doc lib